Michael D. Ehlers, M.D., Ph.D., has decided to step down as Executive Vice President, Research and Development, and will leave Biogen effective October 11, 2019, to pursue a new career opportunity. Under their leadership, Vounatsos said Biogen will continue to aim “sustain leadership in our core MS business and expand our neuroscience portfolio.” Sandrock, who was named CMO in 2012, said he will remain focused on advancing the company’s pipeline in order to bring new treatment options to patients. On March 5, Biogen reported that three individuals who met with their employees at a conference in Boston had tested positive for SARS-CoV-2 the previous week. He held a number of leadership positions at Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology, and general management of Biogen’s Australian and Asia-Pacific business.
in Chemistry and Biology and his M.S. His current focus at Biogen is focusing on neurological and psychiatric diseases. in human biology from Stanford University, an M.D. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases. News Releases You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation: risks relating to management and key personnel changes; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for our products; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; the occurrence of adverse safety events; delay in approval of our drug candidates; potential future healthcare reforms; product liability claims; and third party collaboration risks.
Sandrock received his B.A. Effective immediately, Alfred Sandrock, Jr., M.D., Ph.D., has been named Executive Vice President, Research and Development, in addition to his responsibilities as Chief Medical Officer, and Alphonse Galdes, Ph.D., has been appointed Executive Vice President, Pharmaceutical Operations and Technology. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. Michael D. Ehlers, M.D., Ph.D., has decided to step down as Executive Vice President, Research and Development, and will leave Biogen effective October 11, 2019, to pursue a new career opportunity. He was named Chief Medical Officer in 2012 and since joining the company in 1998, has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. I believe it is the right time to pass the baton, and I am excited about taking on a new challenge in venture capital and biotech with the same broad goal of converting differentiated science into meaningful medicines for patients.”Sandrock has served on Biogen’s Executive Committee since 2015. Michel Vounatsos is not afraid to take a risk. Since joining Biogen in 1995, Galdes has held several senior executive positions, including most recently as Senior Vice President, Asset Development and Portfolio Management from November 2015 to September 2019 and Senior Vice President, Technical Development from October 2010 to November 2015. "I also want to thank Mike for his significant contributions and for the substantial progress made in our pipeline during his three years at Biogen.
from Harvard Medical School and a Ph.D. in neurobiology from Harvard University.